Navigation Links
Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
Date:7/30/2008

egulatory filings are expected in fall 2009. It is anticipated that a BLA will be filed in the United States in the first half of 2010. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

At the 2008 Congress of the European League Against Rheumatism (EULAR) in June, the Company presented three-year data from a long-term Phase 2 continuation trial demonstrating that belimumab was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares and potential steroid-sparing activity. It was also generally well tolerated through three years on treatment in combination with standard of care in patients with serologically active SLE. The results confirm and extend the data presented at previous scientific meetings at earlier time points, including a significant reduction in SLE disease activity as measured by the response rate chosen as the primary efficacy endpoint of the Phase 3 trials.

Oncology Products: Initial Data from HGS-ETR1 Multiple Myeloma Trial Expected Third Quarter 2008; Completion of Randomization in HGS-ETR1 NSCLC Trial Expected Shortly; HGS-ETR1 Hepatocellular Cancer Trial and First Clinical Trial of HGS1029 Initiated

Three randomized chemotherapy combination trials of HGS-ETR1 (mapatumumab) are currently underway to evaluate its potential in the treatment of specific cancers. Together, the three trials comprise a critical proof-of-concept phase in the development of HGS-ETR1:

-- HGS expects to have initial data available in the third quarter of 2008 from a randomized Phase 2 trial of HGS-ETR1 in combination with Velcade (bortezomib) in advanced multiple myeloma.

-- Enrollment is progressing well in the Company's randomized Phase 2 trial of HGS-ETR1 in combination with paclitaxel and carboplatin as first-line therapy in patients with non-small cell lung cancer (NSCLC). HGS now
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
2. Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
3. New map IDs the core of the human brain
4. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
5. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
8. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
9. Robots moving closer to humans
10. Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes
11. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...IK,Iceland,November24/PRNewswire-FirstCall/--deCOD...hasreceivednoticefrom,theNasdaqStockMarketthattrad...vember30,2009andaForm25-NSEwillbefiledwiththe,Secu...scommonstock,fromlistingonNasdaq,unlessthecompanyf....Thecompanyhasfiledsuchanappeal,which,willstaythes...
(Date:11/24/2009)... Health care employment grew by 29,000...ne to show consistent growth during the U.S. reces...ain in trouble, and health systems are coming clos...stead of just administrators. , ...ployment continued growing in October despite the ...
(Date:11/24/2009)...I,Nov.24/PRNewswire-Asia/--NODPharmaceuticalsInc.a...lowedthepatentapplicationfor,itsnano-particleorald...hlyefficientapproachtoincorporatepeptidesor,protei...ryofdrugs,otherwiseadministeredasinjections.NODtec...ymacromoleculardrugssuchasinsulin,interferon,grow...
(Date:11/24/2009)...I,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyannounce...hasapprovedthe,investigationalnewdrugapplication(I...nsulinformulationtotreatdiabetes.ThisIND,approvala... , Diabetesisadisordercharacteristicofhighblo...etesoftenresultinseveremicro-and,macro-vasculardis...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2
...ollowing was issued,today by the Greater Baltimore...O, Greater Baltimore Committee, 140 company owner...rea,bioscience community, WHAT:, The third annua...N:, Tuesday, March 18, 2008, 8:00 a.m. / Breakfa...ram, WHERE:, Renaissance Harborplace Hotel, 202 ...
...rocess, Drive Value from Appraisals, OTTAWA, Marc...ng,provider of web-based employee performance and ... has been selected by Quiznos to provide a system,...adquarters. Quiznos is a,national chain with over ...usy consumers who are looking for a tasty, fresher...
...d Support of National Electronic Disease ...Calif., March 17 Computer,Sciences Corporation (N...ed a,task order from the Centers for Disease Contr... supporting the National Electronic Disease,Survei...m helps the CDC,manage and enhance public health s...
Other Biology Technology:Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Quiznos Selects Halogen for Fresh Approach to Talent Management 2CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order 2
(Date:11/25/2009)... may be just as vital to your health as what you e...ological Studies. Their experiments in mice reveal...f genes in the liverthe body,s metabolic clearingh... the body,s circadian clock as conventional wisdom...vity of a large number of genes completely indepen...
(Date:11/24/2009)...and flabby arteries from collapsing have been true...re no longer needed -- once the arteries are stren...ors had no choice but to leave them in place. , ...partment of Biomedical Engineering has developed a...ugs where they,re needed, then dissolves. , "Our...
(Date:11/24/2009)...d is a matter of debate. A high-profile study a fe...ent of their carbon from trees and leaves, evidenc...d aquatic ecosystems. , But new research from th...y to be true. Algae provide a much richer diet for...h published this week in the Proceedings of the N...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 1AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 3DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 1DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8
...g bones, a healthy immune system, protection again...ere,s yet another item for the expanding list of v...n," keeps the heart, the body,s long-distance runn...gan pharmacologist Robert U. Simpson, Ph.D., think...er." , In studies in rats, Simpson and his team ...
...11, 2008 The J. David Gladstone Institutes today ..., MD, PhD, also of Kyoto University and UCSF, has ...ntributions in reprogramming adult skin cells to p...eive half of the $1 million award. Cloning pioneer...er half of the prize for their landmark generation...
...ational May Concern Law Enforcement Departments, ...ulletin Board: STIY), the leader in electro-stun t...sting law enforcement departments that,have purcha...ade their,weapons in for Stinger S-200 electronic ...ssions., Ron Bellistri, Stinger,s CEO, stated, "I...
Other Biology News:Vitamin D: New way to treat heart failure? 2Vitamin D: New way to treat heart failure? 3Gladstone's Shinya Yamanaka wins prestigious Shaw Prize 2Stinger Systems To Offer Taser Trade-In Program 2
Mouse Anti-Xanthine Oxidase Prediluted Monoclonal Antibody, Unconjugated, Clone SPM325 from Abcam
Mouse Anti-Vancomycin Monoclonal Antibody, Unconjugated, Clone 2G1 from Abcam
Mouse Anti-14-3-3 Binding Motif, phospho (Ser) Monoclonal Antibody, Unconjugated, Clone 4E2 from Cell Signaling Technology
Endotoxin Free Water from Mo Bio Laboratories, Inc.
Biology Products: